• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • Twitter

International Alliance of ALS/MND Associations

  • Members’ Login
  • Contact
  • Join
  • Donate
  • What is ALS/MND?
  • Events
    • Alliance Meeting 2021
    • Allied Professionals Forum 2021
    • ALS/MND Connect 2021
    • International Symposium on ALS/MND 2021
    • Awards
    • Webinars
  • March of Faces
  • Find an Association
  • Support for Members
    • Partnership Programme
    • Mentorship Programme
    • Alliance Support Grant
  • Advocacy
    • Advocacy Toolkit
    • Rights of People with ALS/MND
    • Biogen – Tofersen
    • BrainStorm Cell Therapeutics – NurOwn
    • Collaborative Medicinal Development – CuATSM
    • Cytokinetics – Reldasemtiv
    • Right to Try
    • Unproven (Off-Label) Treatments
    • US FDA Orphan Drug Designation
    • T Regulatory Cell Therapies
    • Amylyx – AMX0035
    • Kadimastem – AstroRx
  • Global Day
  • Resources
    • Submit a Resource
  • Newsletters
  • About
    • About the Alliance
    • Newsletter subscription
    • Board of Directors
    • Committees/Advisory Councils
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Governance Committee
      • Budget and Finance Committee
    • Staff
    • History

Click here for Coronavirus (COVID-19) updates

ALS Therapy Development Institute

(ALS TDI)
United States of America
Date founded: 1999
Region covered:

United States of America and International


Address:

300 Technology Square, 4th Floor
Cambridge, MA 02139 USA


ALS Therapy Development Institute Activities

The mission of the ALS Therapy Development Institute (ALS TDI) is to discover and develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease) as soon as possible for patients today.

Focused on meeting this urgent unmet medical need, ALS TDI executes a robust target discovery program, while simultaneously operating the world’s largest efforts to preclinically validate potential therapeutics; including a pipeline of dozens of small molecules, protein biologics, gene therapies, and cell-based constructs.  Its pipeline is available online and updated regularly. In addition to operating the world’s largest preclinical ALS program, the institute has two clinical stage candidates: TDI-132 (Gilenya) in Phase 2a with assistance from Novartis and TDI-846 (aCD40L) moving forward in partnership with Biogen Idec and UCB Pharma.

The world’s first nonprofit biotech institute, ALS TDI has developed an industrial-scale platform, employs 30 professional scientists, and evaluates dozens of potential therapeutics each year. Since 1999, it has screened more than 200 compounds, more than the rest of the field combined.

In 2008, ALS TDI published the first ever optimized study design for the SOD1 mouse model, which has been now accepted as the basis of all grant applications to many nonprofits such as Prize 4 Life and the MDA. In addition, its guidelines have been echoed by two international consensus meetings to date. It continues to lead in animal model characterization for ALS and related disorders (ie: FTD).

ALS TDI collaborates with leaders in both academia and industry to accelerate ALS therapeutic development, including Biogen Idec, UCB, the Gladstone Institutes, to-BBB, Aestus Therapeutics, the MDA, Driskill, and RGK Foundations. In addition, ALS TDI offers CRO services to pharma, biotech, and academics with an interest in drug development for ALS patients.

Finally, the Institute also maintains an extensive website with podcasts, webcasts, and regular interviews with experts from across the globe on advancements in the diagnosis, tracking, and treatment of ALS. Its staff also maintains a global database of clinical trial listings.

ALS TDI is a 501(c)3 registered charitable nonprofit organization. For more information, please visit us online at www.als.net.

ALS Therapy Development Institute Branches/Chapters

1

Contacts

  • Robert Goldstein, Director of Communications

Phone:

+1 617 441 7295

Fax:

+1 617 441 7299

Email:

info@als.net

Website:

www.als.net

Facebook:

www.facebook.com/ALSTherapyDevelopmentInstitute

Twitter:

twitter.com/ALSTDI

YouTube:

www.youtube.com/user/alstdi

Primary Sidebar

Back to all

Allied Professionals Forum Registration

The International Alliance of ALS/MND Associations will host a virtual Allied Professionals Forum spread over two days to accommodate time zones on 3 – 4 December 2020.

Click here to register for the Allied Professionals Forum

Footer

Support the Alliance

Please donate

Please consider making a donation to support our work. Thank you!

Latest Tweets

  • Creativity takes Courage! (Henri Matisse)In celebration of World Art Day (April 15th), tag an artist or share this… https://t.co/yfn4D6gmmA April 14, 2021 12:00 am
  • https://t.co/aKxWOqKnDZ @AsociacionELAar #ALSMNDWithoutBorders April 13, 2021 8:48 pm
  • maybe there is an opportunity for @TaylorMadeGolf to outfit wheelchairs around the world! #ALSMNDWithoutBorders https://t.co/qWFfwdJ3Eg April 13, 2021 3:36 pm

Keep in touch

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

Return to top of page
  • Disclaimer
  • Privacy notice & Cookies
  • Sitemap

Copyright © 2021 The International Alliance of ALS/MND Associations. All rights reserved.

Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login